...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith Abstract at AACR 2017 Meeting April 1-5

BDAZ – From the Zenith web page under the heading, Program – Prostate Cancer there is a link to a poster presentation http://www.zenithepigenetics.com/upload/media_element/47/01/2016-aacr-poster-final.pdf

Your comment may need modification: I think all we've seen so far is gene modulation 24 hours after administration of the lowest dose.

If I am reading Figs. 2 and 5 correctly in the attached chart it looks like 20 to 22 days of dosing with ZEN3694 were used to measure the change. I am by no means a scientist so please correct me if needed.

Interesting observation, it looks like 2 of the contributors to the poster were from the University of Washington, Seattle.

 

tada

Share
New Message
Please login to post a reply